Partial impairment of cytokine responses in Tyk2-deficient mice - PubMed (original) (raw)

doi: 10.1016/s1074-7613(00)00054-6.

H Neubauer, C Lassnig, P Kovarik, H Schindler, H Pircher, B McCoy, C Bogdan, T Decker, G Brem, K Pfeffer, M Müller

Affiliations

• PMID: 11070173
• DOI: 10.1016/s1074-7613(00)00054-6

Free article

Partial impairment of cytokine responses in Tyk2-deficient mice

M Karaghiosoff et al. Immunity. 2000 Oct.

Free article

Abstract

To assess the role of the Janus kinase (Jak) family member Tyk2, we have generated Tyk2-/- mice. In contrast to other Jaks, where inactivation leads to a complete loss of the respective cytokine receptor signal, Tyk2-/- mice display reduced responses to IFNalpha/beta and IL-12 and a selective deficiency in Stat3 activation in these pathways. Unexpectedly, IFNgamma signaling is also impaired in Tyk2-/- mice. Tyk2-/- macrophages fail to produce nitric oxide upon lipopolysaccharide induction. Tyk2-/- mice are unable to clear vaccinia virus and show a reduced T cell response after LCMV challenge. These data imply a selective contribution of Tyk2 to the signals triggered by various biological stimuli and cytokine receptors.

PubMed Disclaimer

Similar articles

• Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
  Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H. Podewski EK, et al. Circulation. 2003 Feb 18;107(6):798-802. doi: 10.1161/01.cir.0000057545.82749.ff. Circulation. 2003. PMID: 12591746
• Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
  Halfter H, Friedrich M, Postert C, Ringelstein EB, Stögbauer F. Halfter H, et al. Mol Cell Biol Res Commun. 1999 May;1(2):109-16. doi: 10.1006/mcbr.1999.0117. Mol Cell Biol Res Commun. 1999. PMID: 10356359
• Induction of differentiation by IL-6-type cytokines is impaired in myeloid leukaemia cells unable to activate Stat5a.
  Piekorz RP, Hocke GM. Piekorz RP, et al. Cytokine. 1997 Sep;9(9):639-49. doi: 10.1006/cyto.1997.0221. Cytokine. 1997. PMID: 9325012
• Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
  Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Heinrich PC, et al. Biochem J. 1998 Sep 1;334 ( Pt 2)(Pt 2):297-314. doi: 10.1042/bj3340297. Biochem J. 1998. PMID: 9716487 Free PMC article. Review.
• Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
  Muromoto R, Shimoda K, Oritani K, Matsuda T. Muromoto R, et al. Biol Pharm Bull. 2021;44(11):1585-1592. doi: 10.1248/bpb.b21-00609. Biol Pharm Bull. 2021. PMID: 34719635 Review.

Cited by

• Deciphering the modulation of gene expression by type I and II interferons combining 4sU-tagging, translational arrest and in silico promoter analysis.
  Trilling M, Bellora N, Rutkowski AJ, de Graaf M, Dickinson P, Robertson K, Prazeres da Costa O, Ghazal P, Friedel CC, Albà MM, Dölken L. Trilling M, et al. Nucleic Acids Res. 2013 Sep;41(17):8107-25. doi: 10.1093/nar/gkt589. Epub 2013 Jul 5. Nucleic Acids Res. 2013. PMID: 23832230 Free PMC article.
• Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
  Argiriadi MA, Goedken ER, Banach D, Borhani DW, Burchat A, Dixon RW, Marcotte D, Overmeyer G, Pivorunas V, Sadhukhan R, Sousa S, Moore NS, Tomlinson M, Voss J, Wang L, Wishart N, Woller K, Talanian RV. Argiriadi MA, et al. BMC Struct Biol. 2012 Sep 20;12:22. doi: 10.1186/1472-6807-12-22. BMC Struct Biol. 2012. PMID: 22995073 Free PMC article.
• A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses.
  Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, Jonjic S, Koszinowski U, Hengel H. Zimmermann A, et al. J Exp Med. 2005 May 16;201(10):1543-53. doi: 10.1084/jem.20041401. Epub 2005 May 9. J Exp Med. 2005. PMID: 15883169 Free PMC article.
• The role of Tyk2 in regulation of breast cancer growth.
  Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, Conrad D, Larner AC. Zhang Q, et al. J Interferon Cytokine Res. 2011 Sep;31(9):671-7. doi: 10.1089/jir.2011.0023. Epub 2011 Aug 24. J Interferon Cytokine Res. 2011. PMID: 21864028 Free PMC article.
• JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
  Gäbler K, Behrmann I, Haan C. Gäbler K, et al. JAKSTAT. 2013 Jul 1;2(3):e25025. doi: 10.4161/jkst.25025. Epub 2013 May 14. JAKSTAT. 2013. PMID: 24069563 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • GlyGen glycoinformatics resource
  • Mouse Genome Informatics (MGI)

• Miscellaneous

  • NCI CPTAC Assay Portal